I wish all my readers and pharma-industry colleagues a wonderful Thanksgiving holiday!
TODAY’S NEWS
Cephalon, Ception, and CINQUIL: the stats don’t reach significance, but at least all the names are similar – “We are pleased to see a positive biological effect of CINQUIL,” said Steve Tullman, Chief Executive Officer at Ception Therapeutics. “Conducting clinical studies in a new disease area is always challenging. We will continue to review the data from this study and from our ongoing open-label study to find the best path forward for CINQUIL for the treatment of eosinophilic esophagitis.”…more
Might a few companies (such as Endo or King) be targets to go private? WSJ reports.
Can pharma sales reps be turned into better value creators? A question we’re all thinking about…
Duh.
Oops. Abbott’s Meridia weight-loss drug associated with higher rate of cardiovascular events – Meridia is a weight-loss drug approved in 1997. As part of its post-approval commitments, Abbott has been conducting a large study of 10,000 patients to determine whether treatment with Meridia could reduce the number of heart-related adverse events compared to a placebo. In mid-November, however, Abbott reported to regulatory agencies that treatment with Meridia was associated with an 11.4% rate of cardiovascular events compared to 10% for patients treated with placebo…more
RECOMMENDED
HR – leadership, compliance, diversity, and more. The Impactiviti network of providers has solutions, not only for pharma sales training, but for a whole range of corporate and HR training (inside and outside of life sciences). Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
An update on Pfizer’s Social Media initiatives. Encouraging!
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
No comments:
Post a Comment